The price of the Immutep share rose by 57. 14% at the time of writing. The company had some fantastic news to share this morning.
Oddly enough, both updates relate to Phase II trials. With one in full swing and the other slated to begin in the near future.
Your ongoing Phase IIb study has produced some fantastic results. Illustration of the potential of their treatment with eftilaimod alpha (Efti) in combination with chemotherapy. A novel approach to treating a key protein that regulates the body’s immune system.
Anyway, Immutep has found this Efti treatment to be receptive. Even in some patients who are known to be « insensitive » to immune checkpoint inhibitor therapy.
Additionally, efti has shown a mean survival benefit of 2. 7 months in combination with chemotherapy. That is, compared to just chemotherapy alone.
« We are delighted to see that efti boosts the immune system by providing a statistically significant increase in CD8 T cell counts, which correlates with increased patient survival.
« These data provide a proof-of-concept and support our longstanding belief that Efti can provide significant benefit to patients in a range of cancers by » putting pressure on « the body’s immune system, which is a major milestone represents. ‘
Immutep also shared details of a new Phase II breast cancer study scheduled to begin early next year. An investigation that is being overseen by its Chinese partner EOC Pharma.
152 patients with metastatic breast cancer in China will participate in this study. Using a similar randomized and double-blind methodology as in the phase IIb study mentioned above.
This way Immutep can collect even more data from which you can infer. Give them plenty of information to advocate for their Efti treatment – hopefully with the same promising results. Not to mention a launch.
“EOC Pharma shares our growing excitement about the potential for combining Efti with paclitaxel chemotherapy for metastatic breast cancer.
“Our ongoing AIPAC study evaluating the same combination already contains very encouraging data, including a statistically significant survival benefit of 7. 1 month for patients under 65 years of age and 9. 4 months for patients with a low starting monocyte count.
EOC Pharma’s new study in China brings this innovative new treatment much closer to the metastatic breast cancer market. ‘
You have to get a fantastic result to continue your progress. On the long and costly path of drug development.
However, if these early results hold up, they may have a big winner in hand.
For investors, this is exactly what they are hoping for. With this biotechnology, we are gradually approaching the desired result.
You should be aware, however, that trading volatile biotech stocks like Immutep carries a high level of risk. The kind of investment that isn’t for everyone.
So if you are determined to get into high risk stocks, you can benefit from risk mitigation strategies. The kind that our own trading expert – Murray Dawes – has been refining for years.
If you want to learn some of his techniques, check out his free guide here.
Ryan has a degree in communications and international business. He helps Money Morning readers get the latest market updates domestically and internationally. Ryan covers all the questions investors need to know for the mainstream media to neglect.
Ryan is also the editor of the Australian Small-Cap Investigator, a stock tip newsletter that hunts down promising small-cap stocks by analyzing the latest happenings that affect the world.
To learn more about the releases Ryan is working on and how to subscribe to them, please click the appropriate link here:
At Money Morning, our goal is simple: to provide you with intelligent and fun commentary on the day’s most important stock market news and financial info – and tell you how it can benefit you.
All advice is general in nature and has not taken into account your personal circumstances. Please seek advice from an independent financial advisor regarding your own situation or when in doubt about the suitability of an investment.
The value of an investment and the income from it can go down as well as up. Never invest more than you can afford to lose and remember that the ultimate risk is that you can lose everything you invested. While the past is useful for recognizing patterns, it is not an indication of future performance. Some of the figures contained in our reports are projections and may not be a reliable indicator of future results. Actual or potential profits in these reports may not include taxes, brokerage commissions, or related fees.
Immutep, stock, ASX, NASDAQ: IMMP, ASX: IMM, metastatic breast cancer, eftilagimod alpha
World News – USA – Immutep shares rise 57% thanks to two big announcements
. . Related title :
– Immutep updates on the AIPAC- Breast Cancer Study and Announces New Trial
– ASX Share Of The Day: Immutep ( ASX: IMM) Shares Up 60% in Test News
– Immutep Shares Up 57% % higher thanks to two big announcements
– Closing Bell: Today&’s Biggest Small- Cap-Mover at ASX
– The Chinese partner of Immutep& starts the phase II clinical trial for patients with metastas ized breast cancer
– Immutep& # 39; s (ASX: IMM) breast cancer therapy discontinued for phase 2 study in China
– IMMP shares: Immunotep shares rise if breast cancer data is positive
– Immutep 72% after breast cancer study shows promising survival data
– Immutep reports statistically significant survival benefit for important patient groups in the ongoing phase IIb AIPAC study . . .
– Immutep&’s Chinese partner EOC Pharma starts phase II metastatic breast cancer study
Donnez votre avis et abonnez-vous pour plus d’infos
Vidéo du jour: